Antiviral Drugs Market Trends

  • Report ID: 473
  • Published Date: Jul 22, 2024
  • Report Format: PDF, PPT

Antiviral Drugs Market Trends

Growth Drivers

  • Rising Geriatric Population – The rising number of old people across the world and their rising high chances of getting viral infections is estimated to boost the antiviral drugs market growth during the forecast period. Old people are susceptible to diseases due to less immune strength which makes them more prone to any disease or infection. As per the World Health Organization, the number of people aged 60 years and above rose from 1 billion in 2020 to 1.4 billion in 2022.
  • Increased Cases of COVID – 19 – The number of global COVID cases across the world in 2022 was 625,700,400 as per the estimations.
  • Rising Risk of STDs Among Adults – According to the observations, over 1 million sexually transmitted diseases occur each year with an estimated more than 350 new infections.
  • Growing Demand for Generic Versions – As per the IMS Health Institute, the healthcare system of the U.S saved USD 2.2 trillion between 2009 to 2019 with the use of generic drugs.
  • Rising Vaccinations Against Viral Infections – The COVID-19 vaccine was administered in more than 13 billion doses until 2022.

Challenges

  • Increasing Awareness About Preventive Drugs Treatment
  • Presence of Generics
  • Drug Resistance

Antiviral Drugs Market: Key Insights

Base Year

2023

Forecast Year

2024-2036

CAGR

4.1%

Base Year Market Size (2023)

 USD 54.13 Billion

Forecast Year Market Size (2036)

USD 91.27 Billion

Get more information on this report: Request Free Sample PDF

Browse Key Market Insights with Data Illustration:


Author Credits:  Radhika Pawar


  • Report ID: 473
  • Published Date: Jul 22, 2024
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

In the year 2024, the industry size of antiviral drugs is estimated at USD 56.13 Billion.

The antiviral drugs market size was over USD 54.13 Billion in 2023 and is poised to exceed USD 91.27 Billion by the end of 2036, growing at over 4.1% CAGR during the forecast period i.e., between 2024-2036. Rising cases of HIV, AIDS, Hepatitis, and STDs among adults are the major factors driving the market growth.

North America industry is predicted to hold majority revenue share by 2036, driven by growing patient base, the strong foothold of industry key players, increasing approval, and the expected commercialization of new drugs for viral diseases in the region.

AstraZeneca LP, F. Hoffmann-La Roche Ltd, GlaxoSmithKline, Plc, Bristol Myers Squibb Company, Abbott Laboratories, Plough Publishing House, Merck & Co., Inc, Johnson & Johnson Services, Inc, AbbVie Inc., Cipla Inc., Dr Reddy’s Laboratories Ltd.
Inquiry Before Buying Request Free Sample
logo
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying